Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia

A Non-interventional, Multi-center, Retrospective Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia (ROSE Study)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03009721

Enrollment

9707

Registered

2017-01-04

Start date

2016-08-31

Completion date

2018-06-30

Last updated

2017-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemias, Hypertension

Brief summary

The purpose of this study is to investigate the effectiveness and safety of Olostar Tab in patients with essential hypertension and dyslipidemia

Interventions

DRUGOther: Not applicable-observational study

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female ≥ 19 * Patients have record of blood pressure (SBP/DBP) and LDL-C after prescription of Olostar Tab.

Exclusion criteria

* Patients that have participated clinical trials or PMS with Olostar Tab.

Design outcomes

Primary

Measure	Time frame
Percent change from baseline in blood pressure (SBP/DBP)	At 8 Weeks
Percent change from baseline in LDL-Cholesterol (LDL-C)	At 8 Weeks

Countries

South Korea

Contacts

Primary ContactDaewoong Clinical

+82-2-550-8800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026